Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxycycline Injection of Cutaneous Schwannoma in Neurofibromatosis Type 2
NCT05521048Phase 2Active, not recruiting
- Sponsor
- Massachusetts Eye and Ear
- Start
- Sep 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of doxycycline in neurofibromatosis type 2 (NF2), schwannoma, sponsored by Massachusetts Eye and Ear. Started Sep 2022; status: active, not recruiting.
02
Drugs
doxycycline
03
Conditions
neurofibromatosis type 2 (NF2)schwannoma
Beyond the preview
Go deeper on NCT05521048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05521048.